van Houte Hans sold $67K of NRIX
van Houte Hans (Chief Financial Officer) sold 2,845 shares of Nurix Therapeutics, Inc. (NRIX) at $23.38 on 2026-07-30.
How this was made
The 30-second read
Why it matters
The only new fact is the CFO’s open-market sale details (shares, price, total value, post-transaction holdings).
Market read
Traders may monitor insider activity for sentiment, but this filing does not introduce new guidance, trial results, or corporate actions.
What to watch
The article notes no pre-arranged 10b5-1 plan, but it still lacks context on motivations, other holdings, or whether sales were part of broader compensation/financial planning.
Background
The article is a SEC Form 4 insider transaction disclosure for Nurix Therapeutics, Inc.
Ticker impact
Nurix CFO van Houte Hans filed a Form 4 open-market sale of 2,845 shares at $23.3828 on 2026-07-30.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is an open-market sale, not a buy, and it provides no new company-specific operational or financial information.
Market effects
No clear sector read-through from a single routine insider sale.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated.
Key entities
- issuerNurix Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insidervan Houte Hans
Nurix CFO who sold shares via an open-market sale.
